First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations

Filip Jankú, Tae Min Kim, Gopa Iyer, Anna Spreafico, Élena Elez, Maja J.A. de Jonge, Noboru Yamamoto, Anthonie J. van der Wekken, Paolo A. Ascierto, Michela Maur, Frederik Marmé, Jean‐Jacques Kiladjian, Sumit Basu, Fabienne Baffert, Amparo Buigues, Chi Chen, Vesselina G. Cooke, E. Giorgetti, Jaeyeon Kim, Fiona McCarthy, Michele Moschetta, Reinhard Dummer